Search Result

Results for "

SW620

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (3) ADC Payload (1) Adrenergic Receptor (2) Akt (3) AMPK (1) Antibiotic (2) Antibody-Drug Conjugates (ADCs) (1) Apoptosis (27) Arenavirus (1) ATM/ATR (6) Aurora Kinase (1) Autophagy (5) Bacterial (4) Bcl-2 Family (2) Biochemical Assay Reagents (1) Carnitine Palmitoyltransferase (CPT) (1) CDK (13) Checkpoint Kinase (Chk) (2) COX (1) Cyclin G-associated Kinase (GAK) (1) Discoidin Domain Receptor (1) DNA/RNA Synthesis (9) Dopamine Receptor (2) Drug Derivative (3) Drug-Linker Conjugates for ADC (1) DYRK (3) EGFR (2) ERK (3) FAK (1) Ferroptosis (2) Fungal (1) HDAC (1) Heme Oxygenase (HO) (1) HIF/HIF Prolyl-Hydroxylase (3) Histone Methyltransferase (1) HyT (1) Interleukin Related (1) JNK (1) Keap1-Nrf2 (1) Kinesin (1) KLF (1) Lactate Dehydrogenase (1) Ligands for E3 Ligase (1) Ligands for Target Protein for PROTAC (2) Methylenetetrahydrofolate Dehydrogenase (MTHFD) (1) Microtubule/Tubulin (4) Mitochondrial Metabolism (1) Mitosis (1) Mps1 (1) mTOR (1) Necroptosis (1) NEKs (1) NF-κB (3) NO Synthase (1) NOD-like Receptor (NLR) (1) Notch (1) Nuclear Hormone Receptor 4A/NR4A (1) Oxidative Phosphorylation (3) P-glycoprotein (5) p38 MAPK (2) p62 (1) PAK (2) Parasite (1) PARP (5) PASK/STK37 (1) PD-1/PD-L1 (2) PERK (2) Phosphatase (1) PI3K (4) Polo-like Kinase (PLK) (2) PROTAC Linkers (1) PROTACs (9) Radionuclide-Drug Conjugates (RDCs) (1) Ras (17) Reactive Oxygen Species (ROS) (6) Reference Standards (4) SOS1 (2) SphK (1) STAT (5) Topoisomerase (1) Transketolase (1) TROP2 (1) Wnt (3)
By Research Areas:	Cancer (113) Infection (6) Inflammation/Immunology (4) Metabolic Disease (1) Neurological Disease (8)
Click Chemistry:	Alkynes (1)

116

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Inhibitory Antibodies

Natural
Products

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-136057

iFSP1 Maximum Cited Publications 29 Publications Verification	Ferroptosis Ligands for Target Protein for PROTAC	Cancer
iFSP1 is a potent, selective and glutathione-independent inhibitor of ferroptosis suppressor protein 1 (FSP1) (AIFM2) with an EC₅₀ of 103 nM. iFSP1 selectively induces ferroptosis in GPX4-knockout cells which overexpressed FSP1. iFSP1 is able to sensitize a variety of human cancer cell lines to the ferroptosis inducer, such as (1S,3R)-RSL3 (HY-100218A) .

HY-N0220

Dauricine 3 Publications Verification	Oxidative Phosphorylation NF-κB Apoptosis	Neurological Disease Inflammation/Immunology Cancer
Dauricine, a bisbenzylisoquinoline alkaloid in Menispermum dauricum, possesses anti-inflammatory activity. Dauricine inhibits cell proliferation and invasion, and induces apoptosis by suppressing NF-κB activation in a dose- and time-dependent manner in colon cancer .

HY-164702

BL-B01D1 Izalontamab Brengitecan	Antibody-Drug Conjugates (ADCs) EGFR	Cancer
BL-B01D1 is a bispecific ADC, which targets EGFR and HER3 through bispecific antibody Izalontamab (HY-P99676), and exhibits cytotoxicity against various cancer cells via inhibition of DNA replication and DNA synthesis by its ADC toxin ED04 (HY-153891). BL-B01D1 can be used in the study of cancer .

HY-12032

AG14361 5+ Cited Publications	PARP	Cancer
AG14361 is a potent PARP-1 inhibitor, with a K_i of < 5 nM, and in permeabilized SW620 and intact SW620 cells, the IC₅₀s are 29 nM and 14 nM, respectively.

HY-159788

PROTAC K-Ras Degrader-4	PROTACs Ras	Cancer
PROTAC K-Ras Degrader-4 (Compound 4) is a PROTAC degrader for KRAS that degrades KRAS ^G12D in GP5d and degrades KRAS ^G12V in cell SW620 with DC₅₀s of 1 nM and 13 nM. PROTAC K-Ras Degrader-4 inhibits MAPK signaling pathway . (Pink: ligand for target protein pan-KRAS degrader 1 (HY-162960); Black: linker (HY-159790); Blue: ligand for E3 ligase VHL (HY-W998248))

HY-139156

SK-575 5 Publications Verification	PROTACs PARP	Cancer
SK-575 is a highly potent and specific proteolysis-targeting chimera (PROTAC) degrader of PARP1, with an IC₅₀ of 2.30 nM. SK-575 potently inhibits the growth of cancer cells bearing BRCA1/2 mutations .

HY-N0596

Panaxadiol 4 Publications Verification 20(R)-Panaxadiol	PD-1/PD-L1 HIF/HIF Prolyl-Hydroxylase STAT	Cancer
Panaxadiol (20(R)-Panaxadiol) is an orally active HIF-1α/STAT3 inhibitor. Panaxadiol can suppress HIF-1α and STAT3 then lead to downregulation of programmed cell death-ligand 1 (PD-L1) expression. Panaxadiol shows anticancer, cardioprotective, anti-arrhythmic, and antioxidative activities .

HY-136530

SR18662	KLF	Cancer
SR18662 is a potent inhibitor of Krüppel-like factor five (KLF5) with an IC₅₀ of 4.4 nM and an analogue of ML264 (HY-19994) with improved inhibitory potency against colorectal cancer cells. SR18662 can be used for the study of colorectal cancer .

HY-168054

PROTAC K-Ras Degrader-3	PROTACs Ras	Cancer
PROTAC K-Ras Degrader-3 (compound 40) is a PROTAC degrader of K-Ras with a DC₅₀ of ≤ 1 nM against SW620 KRAS G12D, and a GI₅₀ of ≤ 10 nM against SW620 3D cell growth. PROTAC K-Ras Degrader-3 can be utilized in cancer research, such as non-small-cell lung cancer (NSCLC) .

HY-12838

RO5454948 1 Publications Verification Mirk-IN-1; Dyrk1B/A-IN-1	DYRK	Cancer
RO5454948 (Compound 9) is the inhibitor for Dyrk1B and Dyrk1A with IC₅₀ of 68 nM and 22 nM. RO5454948 exhibits cytotoxicity in cancer cell SW620 with EC₅₀ of 1.9 μM .

HY-N0589

Dehydrodiisoeugenol 4 Publications Verification	NF-κB COX Apoptosis Autophagy NO Synthase PERK JNK p38 MAPK CDK NOD-like Receptor (NLR)	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Dehydrodiisoeugenol is an orally active anti-inflammatory and anti-tumor agent. Dehydrodiisoeugenol inhibits the proliferation of colorectal cancer cells, and induces apoptosis, autophagy, endoplasmic reticulum stress and cell cycle arrest. Dehydrodiisoeugenol also exerts anti-inflammatory effects by inhibiting the activation of NF-κB and the expression of COX-2. Dehydrodiisoeugenol can be used in the research related to colorectal cancer, inflammatory diseases and ulcerative colitis .

HY-153090

Transketolase-IN-4	Transketolase	Infection Cancer
Transketolase-IN-4 is a potent inhibitor of transketolase with an IC₅₀ value of 3.9 μM. Transketolase-IN-4 inhibits the proliferation of tumor cells including SW620, LS174T and MIA PaCa-2. Transketolase-IN-4 can be used for tumor research .

HY-144899

ASR-490	Notch	Cancer
ASR-490 reduces the viability of HCT116 and SW620 cells by downregulating Notch1 signaling. ASR-490 overcomes Notch1 overexpression and inhibits the growth of HCT/Notch1 transfectants. ASR-490 inhibits the tumor growth in control (pCMV/HCT116) and Notch1/HCT116 in xenotransplanted mice .

HY-164350

KRAS inhibitor-27	Ras ERK p38 MAPK	Cancer
KRAS inhibitor-27 (Compound 15h) is the inhibitor for KRAS. KRAS inhibitor-27 inhibits KRAS G12D/G12V mutated cells AsPC-1, SW620 and KRAS wildtype cell HT-29 with IC₅₀ of 378, 0.6 and 3230 nM, respectively. KRAS inhibitor-27 inhibits ERK phosphorylation (IC₅₀ in cell AsPC-1 and SW620 is 0.6 nM and 1 nM), reduces the expression of DUSP4, thereby inhibiting MAPK signaling pathway .

HY-100023

LY3177833	CDK	Cancer
LY3177833 (Example 4) is an orally active CDC7 and pMCM2 inhibitor with IC₅₀ values of 3.3 nM and 290 nM, respectively. LY3177833 is a senescence inducer .

HY-150287A

Insulin-Transferrin-Selenium-Ethanolamine ITS-X	Biochemical Assay Reagents	Others
Insulin-Transferrin-Selenium-Ethanolamine (ITS-X) is a cell culture supplement as well as a cell growth and adhesion promoter. Insulin-Transferrin-Selenium-Ethanolamine supports adhesion, pseudopodium formation, pseudopodium elongation and proliferation of adherent cancer cells in serum-free culture systems .

HY-122832

ABC99 1 Publications Verification	Wnt	Cancer
ABC99 is an N-hydroxyhydantoin (NHH) carbamate that selectively inhibits the Wnt-deacylating enzyme NOTUM (IC₅₀=13 nM). ABC99 preserves Wnt3A signaling in the presence of NOTUM .

HY-139065

AMPC	Apoptosis	Cancer
AMPC is a potent and effective TFF3 inhibitor. AMPC inhibits cell proliferation, survival, oncogenicity, and CSC-like behaviour in TFF3-positive CMS4 CRC cells. AMPC acts as a potential anti-cancer agent alone or in combination with 5-FU, and can be used for cancer research .

HY-144256

CHD1Li 6.11	DNA/RNA Synthesis Apoptosis	Cancer
CHD1Li 6.11 is a potent and orally active Chromodomain Helicase DNA Binding Protein 1 Like (CHD1L) (oncogenic gene) inhibitor (IC₅₀ = 3.3 µM for cat-CHD1L recombinant protein). CHD1Li 6.11 can inhibit EMT, induce mesenchymal-epithelial transition (reverse EMT) and promote apoptosis in tumor organoid models. CHD1Li 6.11 can be used for the research of cancer, such as colorectal cancer .

HY-159652

KRAS inhibitor-31 1 Publications Verification	Ras	Cancer
KRAS inhibitor-31 (compound 33) is a KRAS inhibitor, with K_D (SPR) values of 0.019 nM, 0.019 nM and 0.096 nM for KRas G12D, KRas G12C and KRas G12V, respectively .

HY-100195

SAR-020106 1 Publications Verification	Checkpoint Kinase (Chk)	Cancer
SAR-020106 is an ATP-competitive, potent, and selective CHK1 inhibitor with an IC₅₀ of 13.3 nM for human CHK1. SAR-020106 shows excellent selectivity over CHK2. SAR-020106 significantly enhances the cell killing of Gemcitabine and SN38 by 3- to 29-fold in several colon tumor lines and in a p53-dependent fashion. SAR-020106 can enhance antitumor activity with selected anticancer agents .

HY-162809

XMU-MP-9	Ras	Cancer
XMU-MP-9 is a bifunctional compound that binds to the C2 domain of Nedd4-1 and the allosteric site of K-Ras. XMU-MP-9 enhances the interaction between Nedd4-1 and K-Ras, induces conformational changes in the Nedd4-1/K-Ras complex, promotes the ubiquitination and degradation of multiple K-Ras mutants, and inhibits the proliferation of cells carrying K-Ras mutants. XMU-MP-9 can be used for the study of colon, lung and pancreatic cancer .

HY-175870

Eras-4001	Ras	Cancer
Eras-4001 (Compound 14-1) is a pan-KRAS inhibitor. Eras-4001 has potent antitumor activities and significantly inhibits the proliferation of wild-type and mutant (such as KRAS ^G12D, KRAS ^G12V and KRAS ^G12C) cancer cells. Eras-4001 effectively inhibits tumor growth in GP2D and Panc0403 xenograft mouse models .

HY-139848

WS-898	P-glycoprotein	Cancer
WS-898 is a highly effective ABCB1 inhibitor capable of reversing paclitaxel (PTX) resistance in drug-resistant SW620/Ad300, KB-C2, and HEK293/ABCB1 cells (IC₅₀ = 5.0, 3.67, and 3.68 nM, respectively).

HY-118911

ATM Inhibitor-10	ATM/ATR	Cancer
ATM Inhibitor-10 (compound 74), a 3-quinoline carboxamide, is a highly selective and orally active ATM inhibitor (IC₅₀: 0.6 nM). ATM Inhibitor-10 has anti-tumor activity in SW620 xenograft models. ATM Inhibitor-10 is synergistic with Top I inhibitors .

HY-151622

PI3K/mTOR Inhibitor-11 2 Publications Verification	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-11 is an orally active PI3K/mTOR inhibitor (IC₅₀: 3.5, 4.6, and 21.3 nM for PI3Kα, PI3Kδ, and mTOR). PI3K/mTOR Inhibitor-11 regulates the PI3K/AKT/mTOR signaling pathway by inhibiting the phosphorylation of AKT and S6 proteins. PI3K/mTOR Inhibitor-11 can be used in the research of cancers .

HY-162471

GSK_WRN3	DNA/RNA Synthesis ATM/ATR	Cancer
GSK_WRN3 is selective WRN helicase inhibitor (pIC₅₀ = 8.6). SK_WRN3 can selectively inhibit the growth of microsatellite unstable (MSI) cancer cells, induce DNA damage, and cause cell cycle arrest. GSK_WRN3 has anti-tumor activity .

HY-151613A

MS15 TFA	PROTACs Akt	Cancer
MS15 TFA is a potent and selective AKT PROTAC degrader. MS15 TFA inhibits the AKT1, -2, and -3 activities, with IC₅₀ values of 798 nM, 90 nM, and 544 nM, respectively .

HY-158345

PROTAC ATM degrader-1	PROTACs ATM/ATR DNA/RNA Synthesis Apoptosis	Cancer
PROTAC ATM degrader-1 is a ATM PROTAC degrader with a K_D value of 1.17 nM. PROTAC ATM degrader-1 triggers DNA damage response, cell cycle arrest, and apoptosis in cancer cells via the ubiquitin-proteasome-dependent degradation pathway. PROTAC ATM degrader-1 can be used for research on colorectal cancer .

HY-N10113

Verrucarin J Muconomycin B	Apoptosis Arenavirus Fungal Antibiotic Reactive Oxygen Species (ROS)	Infection Cancer
Verrucarin J (Muconomycin B) is a metabolite of the Myrothecium fungus family. Verrucarin J generates reactive oxygen species (ROS) and induces apoptosis of cancer cell lines, such as A549, HCT 116 and SW-620 cells. Verrucarin J shows activities against Candida albicans and Mucor miehei. Verrucarin J inhibits arenavirus Junin (JUNV) yield with an IC₅₀ of 1.2 ng/mL .

HY-132866

YS-370	P-glycoprotein	Cancer
YS-370 (compound 44) is a potent, high selective, and orally active inhibitor of P-glycoprotein (P-gp). YS-370 stimulates the P-gp ATPase activity and has moderate inhibition against CYP3A4. YS-370 effectively reverses multidrug resistance (MDR) to paclitaxel and colchicine in SW620/AD300 and HEK293T-ABCB1 cells. YS-370 in combination with paclitaxel achieves much stronger antitumor activity .

HY-169311

KRAS inhibitor-37	Ras	Cancer
KRAS inhibitor-37 (compound 2) is a potent KRAS inhibitor with K_Ds of 0.004 nM, 0.041 nM, 0.019 nM and 0.144 nM for KRAS wild type, KRAS G12D, KRAS G12C and KRAS G12V by SPR binding assay, respectively. KRAS inhibitor-37 inhibits cell proliferation with IC₅₀s of <2 nM-14 nM for H358, SW620, PANC08.13 cells, respectively. KRAS inhibitor-37 has the potential for cancer research .

HY-176165

CDK9/EZH2-IN-1	CDK Histone Methyltransferase	Cancer
CDK9/EZH2-IN-1 (Compound D16) is a CDK9/EZH2 dual-target inhibitor (IC₅₀: 83.9/108.6 nM). CDK9/EZH2-IN-1 induces apoptosis and DNA double-strand breaks (DSBs). CDK9/EZH2-IN-1 inhibits the proliferation activity of MKN45, MDA-MB-453 and SW620 cancer cells (IC₅₀ values are 136.3, 171.3 and 315.7 nM, respectively) .

HY-116269

AZA197	Ras Apoptosis PAK ERK	Cancer
AZA197 is a selective small molecule inhibitor of Cdc42.AZA197 suppresses colon cancer cell proliferation, cell migration, invasion and increases apoptosis by down-regulating the PAK1 and ERK signaling pathways in vitro. AZA197 reduces tumor growth and significantly increases mouse survival in SW620 tumor xenografts. AZA197 can be used for the study of colon cancer .

HY-128758A

DYRKs-IN-1 hydrochloride	DYRK	Cancer
DYRKs-IN-1 hydrochloride is a potent DYRKs (Dual-specificity tyrosine-phosphorylation-regulated kinases) inhibitor with IC₅₀s of 5 nM and 8 nM for DYRK1A and DYRK1B, respectively. DYRKs-IN-1 hydrochloride has antitumor activity .

HY-76665

Anticancer agent 209	Drug Derivative	Cancer
Anticancer agent 209 (compound 1) is an anticancer agent. Anticancer agent 209 exhibits cytotoxic activity against colon cancer in vitro .

HY-151613

MS15	PROTACs Akt	Cancer
MS15 is a potent and selective AKT PROTAC degrader. MS15 inhibits the AKT1, -2, and -3 activities, with IC₅₀ values of 798 nM, 90 nM, and 544 nM, respectively .

HY-113825

CLK1/2-IN-1	CDK	Cancer
CLK1/2-IN-2 is CLK1 and CLK2 inhibitor with IC₅₀ values of 16 nM and 45 nM, respectively. CLK1/2-IN-2 exhibits potent anti-cancer activities ^{[1] ^.}

HY-164365

PROTAC K-Ras Degrader-2	PROTACs Ras	Cancer
PROTAC K-Ras degrader-2 (compound 48) is a KRAS G12V PROTAC degrader with an IC₅₀ of 20-200 nM for KRAS G12V/RAF1. PROTAC K-Ras degrader-2 degrades SW620 KRAS G12V with a DC₅₀ of 1-10 nM. PROTAC K-Ras degrader-2 inhibits cell growth of SW620 3D cell with an IC₅₀ of ≤10 nM. PROTAC K-Ras degrader-2 can be used for the study of colorectal cancer (CRC) .

HY-12862

Mps1-IN-7	Mps1	Cancer
Mps1-IN-7 is a potent MPS1 inhibitor (IC₅₀ of 0.020 μM) over JNK1 and JNK2 (JNK1 IC₅₀= 0.11 μM, JNK2 IC₅₀=0.22 μM). Mps1-IN-7 inhibit SW620, CAL51, Miapaca-2, RMG1 cell growth with GI₅₀ values of 0.065, 0.068, 0.25, and 0.110 μM,respectively .

HY-168528

WS-917 1 Publications Verification	P-glycoprotein	Cancer
WS-917 is a potent and orally active ABCB1 modulator. WS-917 enhances ABCB1 ATPase activity. WS-917 significantly enhances the antitumor effect of paclitaxel combined with anti-PD-1 antibody. WS-917 promotes CD8 ⁺ T-cell activation .

HY-137990

Questin	Bacterial Parasite Phosphatase	Infection Cancer
Questin is an anthraquinone compound and antibacterial agent. Questin can be isolated from marine-derived fungi and plants. Questin inhibits Cdc25B phosphatase. Questin exhibits antibacterial activity against V. harveyi, V. anguillarum, V. cholerae, and V. parahemolyticus with MIC values of 31.25 µg/mL, 62.5 µg/mL, 62.5 µg/mL, and 125 µg/mL. Questin displays antiprotozoal activity against the animal protozoan pathogen Tritrichomonas foetus, with a MIC of 12.5 µg/mL. Questin has anticancer activity against lung and colon cancer .

HY-161027

2,6-Didehydropeperomin B	Carnitine Palmitoyltransferase (CPT) Apoptosis	Cancer
DHP-B is an Ecolignan-type compound and covalent, selective CPT1A inhibitor with a K_d of 1.62 μM. DHP-B can be isolated from the plant Peperomia dindygulensis. DHP-B covalently binds to Cys96 of CPT1A, blocks FAO, and disrupts the mitochondrial CPT1A-VDAC1 interaction. DHP-B triggers Apoptosis. DHP-B exhibits anti-CRC activity .

HY-153067

Mal-cyclohexane-Gly-Gly-Phe-Gly-Exatecan	Drug-Linker Conjugates for ADC Topoisomerase	Cancer
Mal-cyclohexane-Gly-Gly-Phe-Gly-Exatecan (Compound 11) is a bioactive compound-linker conjugate for ADC. Mal-cyclohexane-Gly-Gly-Phe-Gly-Exatecan can conjugate with antibodies to form ADC (C-11) with anti-tumor activity. Exatecan is a DNA Topoisomerase I inhibitor. Mal-cyclohexane-Gly-Gly-Phe-Gly-Exatecan can be used in the research of squamous cell carcinoma, pancreatic adenocarcinoma and colorectal cancer .

HY-161654

PROTAC SOS1 degrader-10	SOS1 PROTACs Ras	Cancer
PROTAC SOS1 degrader-10 (Compound 11o) is a degrader for son of sevenless 1 (SOS1) in a CRBN and proteasome dependent manner. PROTAC SOS1 degrader-10 degrades SOS1 in KRAS mutant cancer cells SW620, A549 and DLD-1, with DC₅₀s of 2.23, 1.85 and 7.53 nM, respectively. PROTAC SOS1 degrader-10 inhibits the proliferations of cells SW620, A549 and DLD-1, with IC₅₀s of 36.7, 52.2 and 107 nM, respectively. PROTAC SOS1 degrader-10 inhibits phosphorylation of ERK. (Pink: SOS1 ligand (HY-161655); Black: linker (HY-161656); Blue: E3 ligase ligand (HY-W249500))

HY-173329

KRAS-IN-41	Ras	Cancer
KRAS-IN-41 is an inhibitor of KRAS with IC₅₀ values of <0.01 μM for KRAS G12D and KRAS G12V. KRAS-IN-41 inhibits RAS mutant cell lines, GP2D (KRAS-G12D) and SW620 (KRAS-G12V). KRAS-IN-41 can be used in cancer research .

HY-171174

CDK8-IN-16	CDK STAT Wnt	Cancer
CDK8-IN-16 (Compound 51) is an orally active dual inhibitor for CDK8 and CDK19 wih IC₅₀ of 5.1 nM and 5.6 nM. CDK8-IN-16 inhibits the phospho-STAT1 ^SER727 with an IC₅₀ of 17.9 nM in SW620 cell, inhibits WNT signaling pathway with an IC₅₀ of 7.2 nM in 7dF3 cell. CDK8-IN-16 exhibits good pharmacokinetic characteristics in rat models with an oral bioavailability of 57% .

HY-168722

PROTAC PARP1 degrader-3	PARP PROTACs	Cancer
PROTAC PARP1 degrader-3 (Compound C6) is a PROTAC degrader for PARP1 with a DC₅₀ of 58.14 nM. PROTAC PARP1 degrader-3 exhibits cytotoxicity in cancer cell SW-620 and LOVO with IC₅₀ of 1.63 μM and 2.84 μM. PROTAC PARP1 degrader-3 exhibits a synergistic effect with SN-38 (HY-13704) in BRCA-mutated colon cancer cell with a combination index (CI) of 0.487. (Blue: Ligand for E3 ligase Cereblon (HY-23095); Pink: Ligand for target protein (HY-10619); Black: Linker (HY-16872))

HY-100023A

LY3177833 monhydrate	CDK	Cancer
LY3177833 (Example 4) monhydrate is an orally active CDC7 and pMCM2 inhibitor with IC₅₀ values of 3.3 nM and 290 nM, respectively. LY3177833 monhydrate is a senescence inducer .

HY-135900

Aniline-MPB-amino-C3-PBD	ADC Payload Bacterial	Cancer
Aniline-MPB-amino-C3-PBD is a cytotoxic agent comprised non-alkylating group. Aniline-MPB-amino-C3-PBD is a sequence-selective DNA minor-groove binding agent. Aniline-MPB-amino-C3-PBD acts as the payload for ADCs. Antimicrobial activity .

Cat. No.	Product Name	Target	Research Area	Image

HY-P991372

Anti-TROP2 Antibody RN927C antibody	TROP2	Cancer
Anti-TROP2 Antibody (RN927C antibody) is a human monoclonal antibody targeting Trop-2. Anti-TROP2 Antibody exerts in vitro inhibitory effects on a variety of tumor cell lines. Anti-TROP2 Antibody exhibits anti-tumor activity in mouse pancreatic PDX, ovarian PDX, lung PDX and triple-negative breast cancer (TNB) PDX models. Anti-TROP2 Antibody can be used for research on pancreatic cancer, ovarian cancer, lung cancer and triple-negative breast cancer .

Cat. No.	Product Name		Classification

HY-159652

KRAS inhibitor-31 1 Publications Verification		Alkynes
KRAS inhibitor-31 (compound 33) is a KRAS inhibitor, with K_D (SPR) values of 0.019 nM, 0.019 nM and 0.096 nM for KRas G12D, KRas G12C and KRas G12V, respectively .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

SW620

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Inhibitory Antibodies

NaturalProducts

Click Chemistry

Natural
Products